Generated by AI
Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics designed to address the biological drivers of aging and age-related diseases. Its lead program centers on Telomir-1, an oral small molecule being studied for its ability to regulate metal ions and support cellular processes linked to telomere maintenance, epigenetic control, and inflammatory pathways. The company’s research spans a range of therapeutic areas, including oncology, metabolic disorders, ophthalmology, and neurodegenerative conditions. Telomir Pharmaceuticals, Inc. positions its platform around targeting underlying mechanisms rather than isolated symptoms, with current work aimed at advancing therapies for conditions such as triple-negative breast cancer, Wilson’s disease, type 2 diabetes, age-related macular degeneration, Alzheimer’s disease, and Progeria. The company is headquartered in Tampa, Florida.
Website100 SE 2nd Street
Miami, FL, 33131
United States
The latest articles about TELO.
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through
Summary of Apr 30's posts. Generated by AI.
Summary of Nov 21's posts. Generated by AI.
Summary of Nov 21's posts. Generated by AI.
Investors talking about TELO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.